PAK3 Protein (His Tag)

P21 protein (Cdc42/Rac)-activated kinase 3 Protein Datasheet

PAK3 Protein Product Information

• Synonym: RP5-914P14.3, CDKN1A, MRX30, MRX47, OPHN3, PAK3beta, bPAK, Hpak3
• Protein Construction: A DNA sequence encoding the human PAK3 isoform 2 (O75914-2) (Met 1-Arg 544) was fused with a polyhistidine tag at the C-terminus.
• Source: Human
• Expression Host: Baculovirus-Insect cells

PAK3 Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met 1
• Molecular Mass: The recombinant human PAK3 consists of 554 amino acids and predicts a molecular mass of 62 kDa. It migrates as an approximately 60 KDa band in SDS-PAGE in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from 0.2μm filtered solution of 20mM Tris, 500mM NaCl, pH 7.4, 10%glycerol
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: PAK3 protein

PAK3 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

PAK3 Protein Description

PAK3 is a member of PAK proteins, a family of serine/threonine p21-activating kinases, serve as effectors of small Rho GTPases Cdc42 and RAC and have been implicated in a wide range of biological activities. The P21-activated kinase PAK3 is critical for cognitive development and truncating mutations cause non-syndromic mental retardation (MR). In humans, mutations of PAK3 have been associated with mental retardation and result in in vitro studies in defects of spine morphogenesis. Group I p21-activated kinases (PAK1/2/3) is demonstrated as ERK3/ERK4 activation loop kinases. It has been shown that group I PAKs phosphorylate ERK3 and ERK4 on Ser-189 and Ser-186, respectively, both in vitro and in vivo, and that expression of activated Rac1 augments this response. Besides regulation enzymatic activation of ERK3/ERK4, PAKs can also play roles in downstream activation of MAP kinase-activated protein kinase 5 (MK5) in vivo. Thus, the group I PAKs act as upstream activators of ERK3 and ERK4 and unravel a novel PAK-ERK3/ERK4-MK5 signaling pathway. In clinical, PAK has been proposed as a potential therapeutic target in schwannomas.

References

1. Whale A. et al., 2011, Front Biosci. 16: 849-64.
2. Déléris P. et al., 2011, J Biol Chem. 286 (8): 6470-8.
3. Canet B. et al., 2011, Hum Pathol. 42 (6): 833-9.